Search Results
1
Study Matches
The effect of semaglutide in subjects with non-cirrhotic non-alcoholic steatohepatitis
NASH is associated with increased risk of mortality. Currently, there are few treatment options. Therefore, there is a need for an effective and safe medication treatment options. Semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1 RA), can address certain aspects of NASH and is therefore considered a strong candidate for the treatment of NASH.
Gloriany Rivas at stinelaboratory@pennstatehealth.psu.edu or 717-531-0003, ext=320223
All
18 year(s) or older
NCT04822181
Digestive Systems & Liver Disease